The nation of Zimbabwe has declined a major American health deal valued at $367m (£272m) spanning five years over Washington's insistence on confidential information.
This rejection came to light following a government memo from December was leaked, which showed Head of State Emmerson Mnangagwa felt the deal was "skewed".
A government representative later stated that the US was seeking genetic material for scientific study and commercial gain while refused to share the resulting advantages from any future treatments.
"We are forced to start the difficult and regrettable process of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged continued talks to find a deal agreeable to all parties so the nation's critical HIV treatment initiative can proceed.
Wider Implications
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a court halted a similar health funding agreement after concerns were filed about the security of citizens' medical information.
After returning to office recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump argued its expenditure was "wasteful" and his government was seeking government-to-government agreements to enhance transparency and accountability.
According to reports, Sixteen African countries have to date agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Details of the Rejected Agreement
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation could have provided significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on antiretroviral therapy through US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to share its biological resources and data indefinitely, without any corresponding promise of access to any medical innovations – like new medicines or tests – that might be developed from that shared data," his statement read.
"Effectively, our country would supply the raw materials for medical research with no assurance that the final treatments would be available to our citizens if a future disease outbreak arise."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting frameworks previously set up through the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with potential global health emergencies.
"This mechanism is intended to guarantee that when a country contributes its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to create them."
The government's concerns regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our US partners on how future collaboration might be designed in a manner that honours the sovereignty and dignity of each country."
Medical Community Reaction
Medical experts expressed it recognised the official position, but suggested that negotiations should continue considering a large portion of the country's HIV programmes were funded by international support.
"Where specific concerns exist, including those involving information security or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," the group said.
The halted deal underscores the ongoing challenges between accepting crucial foreign assistance and protecting a country's data in an increasingly data-driven world.